Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intismeran autogene plus pembrolizumab in muscle-invasive urothelial carcinoma
NCT06305767Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 16
01
Overview
A Phase 2 trial of intismeran autogene in urothelial carcinoma (UC), sponsored by Merck & Co.. Started Mar 2024; status: active, not recruiting.
02
Drugs
intismeran autogene
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06305767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06305767.